New combo therapy for bile duct cancer enters safety trial
NCT ID NCT06274879
First seen May 27, 2026 · Last updated Jun 19, 2026 · Updated 5 times
Summary
This phase 2 trial is testing whether adding a procedure called radiofrequency ablation (bRFA) to standard chemotherapy and immunotherapy is safe for people with bile duct cancer that cannot be removed by surgery. About 36 participants will be randomly assigned to receive either standard care (stent placement plus drugs) or standard care plus bRFA. The study will track serious side effects and treatment disruptions over six months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILE DUCT CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpitaux Universitaires Genève
NOT_YET_RECRUITINGGeneva, 1205, Switzerland
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Inselspital Bern University Hospital
RECRUITINGBern, 3010, Switzerland
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Luzerner Kantonspital
NOT_YET_RECRUITINGLucerne, 6004, Switzerland
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitätsspital Zürich
NOT_YET_RECRUITINGZurich, 8091, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
radiofrequency ablation
What this could lead to
If successful, this could show that adding radiofrequency ablation to standard treatment is safe, potentially offering a new way to control bile duct cancer.
What could go wrong
This is a small, early-phase trial with only 36 participants, so results may not apply to everyone. The procedure carries risks like infection or bleeding.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.